Rocket Pharmaceuticals, Inc. Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount
Rocket Pharmaceuticals, Inc. (RCKT) had Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount of $45.60 million as of 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized · last filed 2023-02-28
- 2022-12-31: Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $45.60M.
- 2021-12-31: Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $46.30M.
- 2021-03-31: Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $55.70M.
- 2020-12-31: Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $30.40M.
| Period end | Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount |
|---|---|
| 2022-12-31 | $45.60M 10-K · filed 2023-02-28 |
| 2021-12-31 | $46.30M 10-K · filed 2022-02-28 |
| 2021-03-31 | $55.70M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $30.40M 10-K · filed 2022-02-28 |
| 2020-09-30 | $30.50M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $31.60M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $33.00M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $19.30M 10-K · filed 2020-03-06 |
| 2019-09-30 | $20.90M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $22.30M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $24.90M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $18.27M 10-K · filed 2019-03-08 |
| 2018-09-30 | $18.37M 10-Q · filed 2018-11-09 |
| 2018-06-30 | $24.02M 10-Q · filed 2018-08-14 |
| 2018-03-31 | $25.84M 10-Q · filed 2018-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |